Učitavanje...

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma

The oral multikinase inhibitor sunitinib malate was approved by the U.S. Food and Drug Administration in January 2006 for use in patients with advanced renal cell carcinoma (RCC). Since then, it has been approved globally for this indication and for patients with imatinib‐resistant or ‐intolerant ga...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Motzer, Robert J., Escudier, Bernard, Gannon, Andrew, Figlin, Robert A.
Format: Artigo
Jezik:Inglês
Izdano: Wiley-Blackwell 2016
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5313263/
https://ncbi.nlm.nih.gov/pubmed/27807302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0197
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!